| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
|---|
| Outline of Final Research Achievements |
We have developed a dissolving microneedle array for use as a transcutaneous vaccination (TCV) device, and reported that TCV with the dissolving microneedle array induced an immune response against antigens as well as systemic injection. In this study, I searched for the adjuvant which aimed at optimization of TCV. As a result, Monophosphoryl Lipid A (MPLA) and ODN1826 enhanced antibody production against ovalbumin as a model antigen on TCV used dissolving microneedle. ODN1826 and MPLA will be useful as TCV adjuvant.
|
